Combining ARPIs With Radionuclide Therapy Tied to Better Survival in Metastatic CRPC

(MedPage Today) — A secondary analysis of the phase III VISION trial presented at this year’s American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium found that adding androgen receptor pathway inhibitors (ARPIs) to &#185…

Source link : https://www.medpagetoday.com/meetingcoverage/gucsvideopearls/114748

Author :

Publish date : 2025-03-20 15:31:00

Copyright for syndicated content belongs to the linked Source.